Curis (CRIS) announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the company for a private placement for gross proceeds of up to $80.8M to the company, including initial gross proceeds to the company of approximately $20.2M, in each case before placement agent fees and offering expenses. The PIPE financing is expected to close on or about January 8, 2026, subject to the satisfaction of customary closing conditions. Laidlaw & Company is acting as sole placement agent for the PIPE financing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRIS:
- Curis’s Promising Clinical Developments and Strategic Trials Justify Buy Rating
- Curis provides updated data from its frontline AML triplet study
- Promising Early Data from Curis’s Emavusertib Study Supports Buy Rating
- Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating
- Curis Inc. Earnings Call: Clinical Progress and Financial Gains